The Michigan Center for Translational Pathology (MCTP), founded and directed by Dr. Arul Chinnaiyan at the University of Michigan Health System, is a pioneer in precision oncology, being one of the first groups to comprehensively profile advance cancers in a clinically-relevant time frame (see Sci Transl Med. 2011 Nov 30;3(111):111-121.) Building on its early successes, MCTP has continued to refine its testing approach and remains a leader in this dynamic field.
MCTP has developed two precision oncology assays that interrogate different numbers of cancer genes. Using their flagship assay, OncoSeq, MCTP has now profiled over 1,000 patients at the University of Michigan Comprehensive Cancer Center. Results from their pediatric cancer cohort was recently published (See JAMA. 2015 Sep 1;314(9):913-25) and they are currently evaluating their considerable experience in adults. The current version of OncoSeq interrogates around 1,700 cancer genes and has been adapted to both frozen and FFPE tissue samples.
MCTP has also developed the Oncomine Comprehensive Panel (OCP) under the direction of Dr. Scott Tomlins in collaboration with Life Technologies (see Neoplasia. 2015 Apr;17(4):385-99). This assay, focused on solid-tumor testing, interrogates 143 genes and was specifically designed to work with FFPE tissue samples. The OCP assay was selected by the National Cancer Institute (NCI) as the standard assay for the NCI-Match trials currently underway (see http://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match). MCTP will be launching the OCP assay in the coming months.
Our newest Comprehensive NGS Plan includes: